Our results showed that CK1α inhibition could boost the Ibrutinib dependent NF-κB and AKT inactivation, impinging on crucial survival pathways important for MCL clonal expansion such as AKT, NF-κB and BTK. Here, CSNK1A1 is linked to mantle cell lymphoma.